Kestra Medical Technologies’ (KMTS) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a research note published on Wednesday morning,Benzinga reports. BTIG Research currently has a $32.00 price objective on the stock.

A number of other research firms have also commented on KMTS. Wells Fargo & Company increased their price objective on Kestra Medical Technologies from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Piper Sandler boosted their target price on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Monday. The Goldman Sachs Group set a $24.00 price target on shares of Kestra Medical Technologies in a report on Friday, January 16th. Finally, Stifel Nicolaus set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Friday, December 12th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.00.

Kestra Medical Technologies Trading Down 1.1%

Shares of Kestra Medical Technologies stock opened at $19.46 on Wednesday. Kestra Medical Technologies has a 1 year low of $13.25 and a 1 year high of $30.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The business has a 50 day moving average price of $23.67 and a 200 day moving average price of $24.63. The company has a market capitalization of $1.14 billion and a P/E ratio of -4.91.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The company had revenue of $24.55 million for the quarter. The business’s revenue was up 62.7% on a year-over-year basis.

Insider Buying and Selling at Kestra Medical Technologies

In related news, insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $20.27, for a total value of $304,050.00. Following the completion of the transaction, the insider directly owned 364,786 shares in the company, valued at approximately $7,394,212.22. This represents a 3.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Traci S. Umberger sold 10,500 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $26.69, for a total value of $280,245.00. Following the transaction, the insider owned 136,633 shares in the company, valued at $3,646,734.77. This trade represents a 7.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 70,500 shares of company stock valued at $1,709,145 over the last quarter. Insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Kestra Medical Technologies

Several hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. raised its stake in Kestra Medical Technologies by 32.4% during the second quarter. Franklin Resources Inc. now owns 441,398 shares of the company’s stock worth $7,318,000 after purchasing an additional 108,103 shares during the period. Brown Advisory Inc. grew its stake in shares of Kestra Medical Technologies by 5.4% during the 2nd quarter. Brown Advisory Inc. now owns 580,025 shares of the company’s stock valued at $9,617,000 after buying an additional 29,607 shares during the period. Eventide Asset Management LLC grew its stake in shares of Kestra Medical Technologies by 285.7% during the 2nd quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock valued at $17,584,000 after buying an additional 785,557 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Kestra Medical Technologies during the 2nd quarter worth $54,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Kestra Medical Technologies in the 3rd quarter worth $562,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.